OCS Oculis Holding AG

Oculis Holding AG (OCS) is an individual stock. The analysis below presents key financial metrics for the company, covering profitability, capital efficiency, valuation, margins, and growth.

From a returns-on-capital standpoint, ROIC is 109.57%, WACC is 5.51%, and the economic spread is 104.06%. On balance, the gap between ROIC and WACC places this company among the more capital-efficient baskets available. Supporting metrics show ROE at 0.62% and ROA at 5.96%, a combination that helps frame whether profitability strength is broad enough to hold through different market conditions. Taken together, the return profile suggests a company with credible compounding capacity if current operating execution persists.

The company's current market valuation reflects trailing P/E of 0.13. The aggregate current ratio of 8.35 points to strong liquidity for the company. Across multiples and liquidity, the company is priced in a way that reflects current expectations reasonably well — leaving limited room for error, but also limited near-term downside from valuation compression alone.

On profitability at each income statement layer, gross margin sits at N/A, operating margin at -7350.81%, and free cash flow margin at N/A. Gross margin data is unavailable in the current snapshot. Operating margins are negligible or negative, which is typical of portfolios with heavy exposure to businesses still building toward profitability. Free cash flow margin data is unavailable in the current snapshot. Taken together, margins are adequate but uneven, suggesting earnings quality is not uniformly strong across all levels.

Looking at growth and market-implied direction, TTM revenue growth of 18.77% indicating top-line growth that is constructive without being speculative. At the same time, the estimated 12-month price change of 126.08%, where target-based upside appears notably strong in the current setup. It's worth distinguishing between what businesses are actually delivering and what the market is being asked to believe about the next 12 months. Maintaining alignment between reported results and forward estimates is particularly important in periods where macro uncertainty is elevated. The estimated 12-month price change is based on analyst consensus price target estimates, sourced from publicly available data, and should not be interpreted as a reliable prediction of future performance.

Putting the pieces together, this is a profile with genuine merit: the numbers support confidence in the forward case without requiring heroic assumptions.

This assessment is based solely on the quantitative metrics presented above and does not constitute financial advice. Investors should consider their own risk tolerance and conduct independent research before making investment decisions.